Dateline City:
WHITEHOUSE STATION, N.J.
GRASTEK is the Only FDA Approved Sublingual Allergy Immunotherapy Tablet Indicated for Children as Young as 5 Years of Age
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved GRASTEK (Timothy Grass Pollen Allergen Extract)
Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)].
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more